OBJECTIVES: Data on the prevalence of otorhinolaryngological (ORL) symptoms in patients with cystic fibrosis (CF) are limited. A standard annual examination would be useful for definition of risk factors and/or management alternatives for these symptoms. STUDY DESIGN: Prospective observational study of an unselected group of CF patients. PATIENTS AND METHODS: Between 1997 and 2004, 123 CF patients were routinely examined. The examinations included nasal endoscopy and audiological evaluation. RESULTS: All patients who were approached to take part in the study gave their consent and were extremely cooperative. In 40% of the patients nasal polyps were found endoscopically. In 22% rhinological surgery had already been performed. Of the 123 patients, 13 (12%) showed different grades of sensorineural hearing loss, and all of these patients had received aminoglycoside antibiotics. CONCLUSIONS: CF patients demonstrate a high prevalence of ORL symptoms. Therefore, an annual standard examination would provide data for identifying potential risk factors and for optimizing the management of these symptoms in CF patients.
OBJECTIVES: Data on the prevalence of otorhinolaryngological (ORL) symptoms in patients with cystic fibrosis (CF) are limited. A standard annual examination would be useful for definition of risk factors and/or management alternatives for these symptoms. STUDY DESIGN: Prospective observational study of an unselected group of CFpatients. PATIENTS AND METHODS: Between 1997 and 2004, 123 CFpatients were routinely examined. The examinations included nasal endoscopy and audiological evaluation. RESULTS: All patients who were approached to take part in the study gave their consent and were extremely cooperative. In 40% of the patients nasal polyps were found endoscopically. In 22% rhinological surgery had already been performed. Of the 123 patients, 13 (12%) showed different grades of sensorineural hearing loss, and all of these patients had received aminoglycoside antibiotics. CONCLUSIONS:CFpatients demonstrate a high prevalence of ORL symptoms. Therefore, an annual standard examination would provide data for identifying potential risk factors and for optimizing the management of these symptoms in CFpatients.
Authors: J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou Journal: Science Date: 1989-09-08 Impact factor: 47.728
Authors: Louise Gee; Janice Abbott; Anna Hart; Steven P Conway; Christine Etherington; A Kevin Webb Journal: J Cyst Fibros Date: 2005-03 Impact factor: 5.482
Authors: J M Rommens; M C Iannuzzi; B Kerem; M L Drumm; G Melmer; M Dean; R Rozmahel; J L Cole; D Kennedy; N Hidaka Journal: Science Date: 1989-09-08 Impact factor: 47.728
Authors: L C Tsui; M Buchwald; D Barker; J C Braman; R Knowlton; J W Schumm; H Eiberg; J Mohr; D Kennedy; N Plavsic Journal: Science Date: 1985-11-29 Impact factor: 47.728
Authors: B J Wainwright; P J Scambler; J Schmidtke; E A Watson; H Y Law; M Farrall; H J Cooke; H Eiberg; R Williamson Journal: Nature Date: 1985 Nov 28-Dec 4 Impact factor: 49.962
Authors: Jochen G Mainz; Andrea Gerber; Michael Lorenz; Ruth Michl; Julia Hentschel; Anika Nader; James F Beck; Mathias W Pletz; Andreas H Mueller Journal: Case Rep Infect Dis Date: 2015-03-18
Authors: Korneliusz Golebski; Xavier R Ros; Maho Nagasawa; Sophie van Tol; Balthasar A Heesters; Hajar Aglmous; Chantal M A Kradolfer; Medya M Shikhagaie; Sven Seys; P W Hellings; Cornelis M van Drunen; Wytske J Fokkens; Hergen Spits; Suzanne M Bal Journal: Nat Commun Date: 2019-05-14 Impact factor: 14.919